Journal article
Cd44v6 defines a new population of circulating tumor cells not expressing epcam
G Belthier, Z Homayed, F Grillet, C Duperray, J Vendrell, I Krol, S Bravo, JC Boyer, O Villeronce, J Vitre-Boubaker, D Heaug-Wane, F Macari-Fine, J Smith, M Merlot, G Lossaint, T Mazard, F Portales, J Solassol, M Ychou, N Aceto Show all
Cancers | MDPI | Published : 2021
Open access
Abstract
Circulating tumor cells (CTCs) are promising diagnostic and prognostic tools for clinical use. In several cancers, including colorectal and breast, the CTC load has been associated with a therapeutic response as well as progression-free and overall survival. However, counting and isolating CTCs remains sub-optimal because they are currently largely identified by epithelial markers such as EpCAM. New, complementary CTC surface markers are therefore urgently needed. We previously demonstrated that a splice variant of CD44, CD44 variable alternative exon 6 (CD44v6), is highly and specifically expressed by CTC cell lines derived from blood samples in colorectal cancer (CRC) patients. Two differe..
View full abstractGrants
Awarded by Ligue Contre le Cancer
Funding Acknowledgements
Grant INCa-DGOS-Inserm 6045; region Languedoc-Roussillon for the Chercheur dAvenir Grant; la Ligue Contre le Cancer for funding G.B. and Z.H.